HER2/neu detection by immunohistochemistry: Optimization of in-house protocols

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 2, 2009, Pages 151-157

  Lourenço, Hugo M ^a   Pereira, Teresa P ^a   Fonseca, Ricardo R ^a,b   Cardoso, Paula M ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

HER2; Immunohistochemistry; Optimization; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANTIGEN RETRIEVAL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC KIT; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 67849130148     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318186f0dc     Document Type: Article

References (22)

1. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erbB-related gene encoding 185,000-Mr tumour antigen. Nature. 1984;312:513-516. (Pubitemid 15182278)
2. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132-1139. (Pubitemid 16169997)
3. Ross J, Fletcher J. The Her-2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Stem Cells. 1998;16:416-428. (Pubitemid 28399649)
4. Ellis CM, Dyson MJ, Stephenson TJ, et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridization using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 2005;58:710-714.
5. Plunkelt TA, Miles DW. New biological therapies for breast cancer. Int J Clin Pract. 2002;56:261-266. (Pubitemid 34625024)
6. National Institute for Clinical Excellence. Technology Appraisal No 34. Guidance on the use of trastuzumab for the treatment of advanced breast cancer 2002.
7. Ellis IO, Bartlett J, Dowsett M, et al. Updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004;57:233-237.
8. DAKO HercepTest™ for the TechMate™ Instruments. For immunocytochemical staining, 2004 (Package Insert); DakoCytomation Denmark A/S, Glostrup, Denmark.
9. Determination of HER2 by fluorescence in situ hybridization (FISH) in breast cancer. Experience of the reference laboratory of Lisbon. Acta Med Port. 2005;18:417-422.
10. Hanna W, O'Malley FP, Barnes P, et al. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncl. 2007;14:149-153.
11. Zarbo RJ, Hammond EH. Her-2 testing of breast cancer patients in clinical practice. Arch Pathol Lab Med. 2003;127:549-553.
12. Perez MEA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
13. Packeisen J, Buerger H, Krech R, et al. Tissue microarrays: a new approach for quality control in immunohistochemistry. J Clin Pathol. 2002;55:244-248. (Pubitemid 34888306)
14. Hsu FD, Nielsen TO, Alkushi A, et al. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol. 2002;15:1374-1380. (Pubitemid 35463007)
15. Gouvêa AP, Milanezi F, Olson SJ, et al. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol. 2006; 14:103-108.
16. Rhodes A, Jasani B, Anderson E, et al. Evaluation of HER2/neu immunohistochemical assay sensitivity and scoring on formalin- fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol. 2002;118:408-417. (Pubitemid 37046339)
17. Ricardo SA, Milanezi F, Carvalho ST, et al. HER2 evaluation through the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. JCP Online First; December 8, 2006; 10.1136/jcp.2006.040287.
18. Miller K. The breast HER-2 module-best methods. Immunocytochemistry. 2006;5:28-33.
19. Morgan JM, Navabi H, Jasani B. Role of calcium chelation in hightemperature antigen retrieval at different pH values. J Pathol. 1997; 182:233-237. (Pubitemid 27287847)
20. Shi S-R, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry: past, present and future. J Histochem Cytochem. 1997;45: 327-343. (Pubitemid 27120589)
21. Emoto K, Yamashita S, Okada Y. Mechanisms of heat-induced antigen retrieval: does pH or ionic strength of the solution play a role for refolding antigens? J Histochem Cytochem. 2005;53: 1311-1321.
22. Gulmann C, Loring P, O'Grady A, et al. Miniature tissue microarrays for HercepTest™ standardisation and analysis. J Clin Pathol. 2004;57:1229-1231. (Pubitemid 39486536)